Cutler Group LP Atossa Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Oct 25, 2022	SELL	$0.82 - $1.14 $245 - $341	-300 Reduced 0.93%	32,100 $3,000
Q2 2022 Aug 04, 2022	SELL	$0.85 - $1.28 $8,415 - $12,672	-9,900 Reduced 23.4%	32,400 $3,000
Q1 2022 Apr 14, 2022	SELL	$1.11 - $1.74 $181,374 - $284,316	-163,400 Reduced 79.44%	42,300 $4,000
Q4 2021 Jan 18, 2022	SELL	$1.6 - $3.27 $359,840 - $735,423	-224,900 Reduced 52.23%	205,700 $14,000
Q3 2021 Oct 26, 2021	SELL	$2.89 - $6.4 $1.54 Million - $3.4 Million	-531,200 Reduced 55.23%	430,600 $174,000
Q2 2021 Jul 19, 2021	BUY	$1.52 - $8.62 $1.12 Million - $6.37 Million	738,700 Added 331.11%	961,800 $2.4 Million
Q1 2021 Apr 26, 2021	BUY	$0.92 - $4.33 $204,700 - $963,425	222,500 Added 37083.33%	223,100 $116,000
Q4 2020 Jan 21, 2021	SELL	$0.85 - $2.43 $8,840 - $25,272	-10,400 Reduced 94.55%	600 $0
Q3 2020 Oct 27, 2020	BUY	$1.98 - $4.35 $11,286 - $24,794	5,700 Added 107.55%	11,000 $1,000
Q2 2020 Jul 22, 2020	BUY	$1.04 - $4.05 $5,512 - $21,465	5,300 New	5,300 $8,000

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $154M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.